Skip to main content
Retour
ABT logo

Abbott Laboratories

Qualité des données : 100%
ABT
NYSE Healthcare Medical - Devices
104,06 €
▼ 0,79 € (-0,75%)
Cap. Boursière : 180,82B
Fourchette du Jour
102,41 € 104,25 €
Fourchette 52 Semaines
102,41 € 139,06 €
Volume
11 747 104
Moyenne 50J / 200J
113,11 € / 125,68 €
Clôture Précédente
104,85 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 27,7 0,4
P/B 3,5 2,9
ROE % 13,1 3,7
Net Margin % 14,7 3,9
Rev Growth 5Y % 0,7 10,0
D/E 0,3 0,2

Objectif de Cours des Analystes

Hold
137,67 € +32.3%
Low: 120,00 € High: 158,00 €
P/E Prévisionnel
18,5
BPA Prévisionnel
5,68 €
Croissance BPA (est.)
+0,0%
CA Est.
48 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 8,36 €
8,22 € – 8,71 €
63 B 4
FY2029 7,56 €
7,43 € – 7,88 €
59 B 4
FY2028 6,87 €
5,93 € – 7,45 €
55 B 11

Insider Trading Activity

Buy ratio (90d) 0.0%
20 transactions
Date Insider Type Shares Price Value
Mar 2, 2026
Shroff Eric
Senior Vice President
sell 709 115,58 € 81 946 €
Mar 2, 2026
Cushman Elizabeth C.
EVP, GC AND SECRETARY
sell 263 115,58 € 30 398 €
Mar 2, 2026
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
sell 1 144 115,58 € 132 224 €
Feb 27, 2026
Shroff Eric
Senior Vice President
other 1 384 116,26 € 160 904 €
Feb 27, 2026
Boudreau Philip P
EVP AND CFO
other 7 441 116,26 € 865 091 €
Feb 27, 2026
Ford Robert B
CHAIRMAN AND CEO
other 30 308 116,26 € 3 523 608 €
Feb 27, 2026
Cushman Elizabeth C.
EVP, GC AND SECRETARY
other 1 421 116,26 € 165 205 €
Feb 27, 2026
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
other 4 040 116,26 € 469 690 €
Feb 24, 2026
Ford Robert B
CHAIRMAN AND CEO
grant 427 530
Dec 31, 2025
Stratton John G
grant 313 125,29 € 39 216 €
Dec 31, 2025
Roman Michael F
grant 301 125,29 € 37 712 €
Dec 11, 2025
Salvadori Daniel Gesua Sive
EVP AND GROUP PRESIDENT
other 1 536 123,28 € 189 358 €
Sep 30, 2025
Stratton John G
grant 293 133,94 € 39 244 €
Jun 30, 2025
Stratton John G
grant 282 136,01 € 38 355 €
Jun 30, 2025
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
other 269 134,38 € 36 148 €
Jun 30, 2025
Gonzalez Patricia Paola
grant 242 136,01 € 32 914 €
Apr 30, 2025
Blount Sally E.
sell 2 600 129,66 € 337 116 €
Apr 25, 2025
Roman Michael F
grant 1 635
Apr 25, 2025
McDew Darren W
grant 1 635
Mar 31, 2025
Gonzalez Patricia Paola
grant 248 132,65 € 32 897 €

Points Clés

Revenue grew 0,72% annually over 5 years — modest growth
Earnings declined -51,32% over the past year
ROE of 13,07% — decent returns on equity
Debt/Equity of 0,29 — conservative balance sheet
Generating 7,40B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 4,95%

Croissance

Revenue Growth (5Y)
0,72%
Revenue (1Y)5,67%
Earnings (1Y)-51,32%
FCF Growth (3Y)20,90%

Qualité

Return on Equity
13,07%
ROIC8,98%
Net Margin14,72%
Op. Margin18,16%

Sécurité

Debt / Equity
0,29
Current Ratio1,58
Interest Coverage23,60

Valorisation

P/E Ratio
27,72
P/B Ratio3,47
EV/EBITDA23,28
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5,67% Revenue Growth (3Y) 5,13%
Earnings Growth (1Y) -51,32% Earnings Growth (3Y) 6,77%
Revenue Growth (5Y) 0,72% Earnings Growth (5Y) -1,99%
Profitability
Revenue (TTM) 44,33B Net Income (TTM) 6,52B
ROE 13,07% ROA 7,52%
Gross Margin 55,51% Operating Margin 18,16%
Net Margin 14,72% Free Cash Flow (TTM) 7,40B
ROIC 8,98% FCF Growth (3Y) 20,90%
Safety
Debt / Equity 0,29 Current Ratio 1,58
Interest Coverage 23,60 Dividend Yield 0,02%
Valuation
P/E Ratio 27,72 P/B Ratio 3,47
P/S Ratio 4,08 PEG Ratio -0,65
EV/EBITDA 23,28 Dividend Yield 0,02%
Market Cap 180,82B Enterprise Value 187,37B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 44,33B 41,95B 40,11B 43,65B 43,08B
Net Income 6,52B 13,40B 5,72B 6,93B 7,07B
EPS (Diluted) 3,72 7,64 3,27 3,91 3,94
Gross Profit 24,61B 21,33B 20,04B 22,32B 23,21B
Operating Income 8,05B 6,83B 6,44B 8,36B 9,20B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 86,71B 81,41B 73,21B 74,44B 75,20B
Total Liabilities 33,94B 33,51B 34,39B 37,53B 39,17B
Shareholders' Equity 52,13B 47,66B 38,60B 36,69B 35,80B
Total Debt 15,07B 15,28B 15,87B 17,95B 19,25B
Cash & Equivalents 8,52B 7,62B 6,90B 9,88B 9,80B
Current Assets 26,00B 23,66B 22,67B 25,22B 24,24B
Current Liabilities 16,50B 14,16B 13,84B 15,49B 13,11B

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#685 of 1024
37

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026